scispace - formally typeset
S

Sue Jowett

Researcher at University of Birmingham

Publications -  189
Citations -  6844

Sue Jowett is an academic researcher from University of Birmingham. The author has contributed to research in topics: Randomized controlled trial & Cost effectiveness. The author has an hindex of 34, co-authored 169 publications receiving 5663 citations. Previous affiliations of Sue Jowett include University of Cambridge & Arthritis Research UK.

Papers
More filters
Journal ArticleDOI

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

TL;DR: Flexible dosing of MMT and BMT appears to be similarly effective whether delivered in a primary care or outpatient clinic setting, and in a direct comparison, MMT was found to be slightly more effective and less costly than BMT.
Journal ArticleDOI

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

TL;DR: All three agents, either alone (where so licensed) or in combination with ongoing disease-modifying antirheumatic drugs (DMARDs), were effective in reducing the symptoms and signs of RA in patients with established disease.
Journal ArticleDOI

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial

TL;DR: Active screening for atrial fibrillation detects additional cases over current practice, and the preferred method of screening in patients aged 65 or over in primary care is opportunistic pulse taking with follow-up electrocardiography.
Journal ArticleDOI

A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

TL;DR: The results of the study indicated that in terms of a screening programme for atrial fibrillation in patients 65 and over, the only strategy that improved on routine practice was opportunistic screening, and model-based analyses indicated that there was a probability of approximately 60% of annual opportunistic screenings being cost effective.